Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies

Table 1 A summary of the drugs used in this study and their inhibitory spectrum against the cellular kinome

Name	Concentration used	Main kinase target	Reference
Cetuximab	30 μM	EGFR (Epidermal Growth Factor Receptor)	[7]
Erlotinib	1 μM	EGFR	[15]
Afatinib	10 μM	EGFR / ErbB2/ ErbB4	[15]
Sorafenib	10 μM	B-RAF, C-RAF, PDGFR-A, PDGFR-B (Platelet-Derived Growth Factor Receptor)	[15]
Sorafenib	10 μM	VEGFR-2 (Vascular Endothelial Growth Factor-2)	[15]
Masitinib	10 μM	KIT, PDGFR-A, PDGFR-B	[15]
Tivantinib	10 μM	HGFR (Hepatocyte Growth Factor Receptor)	[16]
Ponatinib	1 μM	FGFR1-4 (Fibroblast-Growth Factor Receptor), PDGFR-A, VEGFR-2	[17]
Rapamycin	1 μM	mTOR (mammalian Target Of Rapamycin)	[18]

ISSN: 1471-2407